X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Pfizer - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs PFIZER - Comparison Results

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES PFIZER VENUS REMEDIES/
PFIZER
 
P/E (TTM) x -836.6 28.8 - View Chart
P/BV x 0.2 4.6 5.3% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 VENUS REMEDIES   PFIZER
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
PFIZER
Mar-16
VENUS REMEDIES/
PFIZER
5-Yr Chart
Click to enlarge
High Rs2182,724 8.0%   
Low Rs821,611 5.1%   
Sales per share (Unadj.) Rs365.6440.9 82.9%  
Earnings per share (Unadj.) Rs1.548.7 3.1%  
Cash flow per share (Unadj.) Rs37.975.8 50.0%  
Dividends per share (Unadj.) Rs015.00 0.0%  
Dividend yield (eoy) %00.7 0.0%  
Book value per share (Unadj.) Rs382.5462.9 82.6%  
Shares outstanding (eoy) m11.4445.75 25.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.44.9 8.3%   
Avg P/E ratio x101.044.5 226.8%  
P/CF ratio (eoy) x4.028.6 13.8%  
Price / Book Value ratio x0.44.7 8.4%  
Dividend payout %030.8 0.0%   
Avg Mkt Cap Rs m1,71799,163 1.7%   
No. of employees `0001.02.9 35.3%   
Total wages/salary Rs m3242,758 11.8%   
Avg. sales/employee Rs Th4,100.76,981.7 58.7%   
Avg. wages/employee Rs Th318.0954.5 33.3%   
Avg. net profit/employee Rs Th16.7771.1 2.2%   
INCOME DATA
Net Sales Rs m4,18320,170 20.7%  
Other income Rs m20857 2.3%   
Total revenues Rs m4,20321,028 20.0%   
Gross profit Rs m8124,310 18.8%  
Depreciation Rs m4171,239 33.6%   
Interest Rs m3805 7,303.8%   
Profit before tax Rs m353,923 0.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m099 0.0%   
Tax Rs m181,794 1.0%   
Profit after tax Rs m172,228 0.8%  
Gross profit margin %19.421.4 90.8%  
Effective tax rate %51.645.7 112.7%   
Net profit margin %0.411.0 3.7%  
BALANCE SHEET DATA
Current assets Rs m2,77116,299 17.0%   
Current liabilities Rs m1,9317,594 25.4%   
Net working cap to sales %20.143.2 46.5%  
Current ratio x1.42.1 66.8%  
Inventory Days Days12565 191.6%  
Debtors Days Days5426 208.7%  
Net fixed assets Rs m5,3288,622 61.8%   
Share capital Rs m114458 25.0%   
"Free" reserves Rs m4,17720,722 20.2%   
Net worth Rs m4,37621,180 20.7%   
Long term debt Rs m1,91125 7,642.0%   
Total assets Rs m8,42829,137 28.9%  
Interest coverage x1.1755.5 0.1%   
Debt to equity ratio x0.40 36,985.4%  
Sales to assets ratio x0.50.7 71.7%   
Return on assets %4.77.7 61.4%  
Return on equity %0.410.5 3.7%  
Return on capital %6.619.0 34.7%  
Exports to sales %00.1 0.0%   
Imports to sales %20.517.5 117.4%   
Exports (fob) Rs mNA12 0.0%   
Imports (cif) Rs m8583,526 24.3%   
Fx inflow Rs m052 0.0%   
Fx outflow Rs m858140 613.2%   
Net fx Rs m-858-88 971.7%   
CASH FLOW
From Operations Rs m4693,436 13.6%  
From Investments Rs m29-6,991 -0.4%  
From Financial Activity Rs m-464-619 74.9%  
Net Cashflow Rs m35-4,174 -0.8%  

Share Holding

Indian Promoters % 32.9 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 0.2 7.5 2.4%  
FIIs % 0.6 4.9 11.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 23.7 280.2%  
Shareholders   20,121 85,207 23.6%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   UNICHEM LAB  SUN PHARMA  PIRAMAL ENTERPRISES  GLENMARK PHARMA  SHASUN PHARMA  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of Global Markets Hitting Record Highs and Top Stocks in Action During the Week(RoundUp)

Global stock markets ended the week on a positive note. Benchmark indices in US grew by 1% during the week. The Down Jones Industrial Average topped the 26,000.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Jan 19, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - ALEMBIC PHARMA COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS